SCHEMBL245158

SCHEMBL245158

BrCc1cccc(CBr)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.55
KCNH2 Q12809 4/20 0.46
PGK1 P00558 1/20 0.42
PGK2 P07205 1/20 0.42
HRH4 Q9H3N8 1/20 0.41
GRIN2D O15399 2/20 0.39
GRIN3B O60391 2/20 0.39
GRIN1 Q05586 2/20 0.39
GRIN2A Q12879 2/20 0.39
GRIN2B Q13224 2/20 0.39
GRIN2C Q14957 2/20 0.39
GRIN3A Q8TCU5 2/20 0.39
NPSR1 Q6W5P4 1/20 0.38
CXCR4 P61073 3/20 0.37
TRPA1 O75762 1/20 0.36
ALDH1A1 P00352 1/20 0.36
TSHR P16473 1/20 0.36
NOS1 P29475 1/20 0.34
NOS2 P35228 1/20 0.34
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL1259355 0.97 CCR1 (0.52) CCR1KCNH2PGK1PGK2HRH4
SCHEMBL18131277 0.87 CCR1 (0.44) CCR1KCNH2PGK1PGK2HRH4
SCHEMBL4046726 0.87 KCNH2 (0.48) CCR1KCNH2PGK1PGK2HRH4
SCHEMBL243652 0.87 CCR1 (0.44) CCR1KCNH2PGK1PGK2HRH4
SCHEMBL2840767 0.87 CCR1 (0.44) CCR1KCNH2PGK1PGK2HRH4
SCHEMBL3167663 0.86 CCR1 (0.48) CCR1KCNH2PGK1PGK2HRH4
SCHEMBL29561513 0.84
SCHEMBL506617 0.84
SCHEMBL9146011 0.84 CCR1 (0.46) CCR1KCNH2PGK1PGK2HRH4
SCHEMBL4045371 0.83 KCNH2 (0.61) CCR1KCNH2GRIN2DGRIN3BGRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 831 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120136929-A Ruthenium-based catalyst, preparation method thereof and application of ruthenium-based catalyst in preparation of hydrogenated nitrile rubber in organic solvent 山东链科新材料有限公司 2025-06-13 CN claimed
US-20250101475-A1 MONOOXYGENASE MUTANTS FOR BIOSYNTHESIS OF 2,6-BIS(HYDROXYMETHYL)PYRIDINE AND A METHOD FOR PREPARATION OF 2,6-BIS(HYDROXYMETHYL)PYRIDINE USING THE SAID MONOOXYGENASE MUTANTS VIO CHEMICALS AG (CH) 2025-03-27 US claimed
CN-118871588-A Monooxygenase mutants for biosynthesis of 2, 6-bis (hydroxymethyl) pyridine and method for preparing 2, 6-bis (hydroxymethyl) pyridine using same VIO化学公司 2024-10-29 CN claimed
US-20240182526-A1 COMPOSITIONS AND METHODS FOR MODULTING INFLAMMATORY AND DEGENERATIVE DISORDER UNIV SOUTHERN CALIFORNIA (US) 2024-06-06 US claimed
CN-117384159-A Preparation method and application of long conjugated pyridinium macrocyclic photosensitizer 暨南大学 2024-01-12 CN claimed
CN-113683645-B Binuclear Pt (II) complex with anti-tumor activity and preparation method and application thereof 湖北科技学院 2023-11-07 CN claimed
CN-115246797-B Azacrown ether compound, and preparation method and application thereof 中国科学院上海高等研究院 2023-07-21 CN claimed
WO-2023126510-A1 MONOOXYGENASE MUTANTS FOR BIOSYNTHESIS OF 2,6-BIS(HYDROXYMETHYL)PYRIDINE AND A METHOD FOR PREPARATION OF 2,6-BIS(HYDROXYMETHYL)PYRIDINE USING THE SAID MONOOXYGENASE MUTANTS VIO CHEMICALS AG (CH) 2023-07-06 WO claimed
CN-115246797-A Aza-crown ether compound and preparation method and application thereof 中国科学院上海高等研究院 2022-10-28 CN claimed
WO-2022212513-A1 COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATORY AND DEGENERATIVE DISORDER UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2022-10-06 WO claimed
US-20160083430-A1 PEPTIDE AND PEPTIDOMIMETIC INHIBITORS RA PHARMACEUTICALS, INC. 2016-03-24 US claimed
US-9238676-B2 Peptide and peptidomimetic inhibitors RA PHARMACEUTICALS, INC. (US) 2016-01-19 US claimed
WO-2015191951-A2 MODULATION OF COMPLEMENT ACTIVITY RA PHARMACEUTICALS, INC. (US) 2015-12-17 WO claimed
US-20150166606-A1 PEPTIDE AND PEPTIDOMIMETIC INHIBITORS RA PHARMACEUTICALS, INC. 2015-06-18 US claimed
EP-2850095-A1 PEPTIDE AND PEPTIDOMIMETIC INHIBITORS RA Pharmaceuticals, Inc. (US) 2015-03-25 EP claimed
EP-2216372-B1 Compounds for preventing Ghost odour THOR GMBH (DE) 2014-06-04 EP claimed
WO-2013172954-A1 PEPTIDE AND PEPTIDOMIMETIC INHIBITORS RA PHARMACEUTICALS, INC (US) 2013-11-21 WO claimed
US-7618913-B2 Coordination catalyst containing an organosilicon compound , nitrogen compound, transition metal compound and magnesiumon compound on catalyst support FORMOSA PLASTICS CORPORATION, U.S.A. (US) 2009-11-17 US claimed
WO-2008027479-A2 HIGHLY ACTIVE ALPHA-OLEFIN COPOLYMERIZATION CATALYST SYSTEM FORMOSA PLASTICS CORPORATION, U.S.A. (US) 2008-03-06 WO claimed
US-20080058198-A1 Highly active alpha-olefin copolymerization catalyst system FORMOSA PLASTICS CORPORATION, U.S.A. 2008-03-06 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150166606-A1 PEPTIDE AND PEPTIDOMIMETIC INHIBITORS KLKB1, KLK1, KLK5 CCR1 905/4885KCNH2 2254/4885PGK1 979/4885
US-20160083430-A1 PEPTIDE AND PEPTIDOMIMETIC INHIBITORS KLKB1, KLK1, KLK5 CCR1 905/4885KCNH2 2254/4885PGK1 979/4885
US-20240182526-A1 COMPOSITIONS AND METHODS FOR MODULTING INFLAMMATORY AND DEGENERATIVE DISORDER TNF, AGER, GRN CCR1 1585/4885KCNH2 4086/4885PGK1 2782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.